12:00 AM
 | 
Dec 15, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CCX140: Additional Phase II data

Additional data from a 52-week, double-blind, European Phase II trial in 196 evaluable patients with diabetic nephropathy showed once-daily 5 mg oral CCX140 plus standard of care (SOC) met the primary endpoint of reducing UACR over 52 weeks vs. SOC alone (p=0.0148). The 5 mg dose of CCX140 plus SOC led to a maximum...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >